Bioaffinity Technologies, Inc. (BIAF) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bioaffinity Technologies, Inc. on April 25, 2023. The company is incorporated in Delaware and its common stock (BIAF) and tradeable warrants (BIAFW) are listed on The Nasdaq Stock Market LLC. The registrant is classified as an emerging growth company.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report does not contain financial statements or performance metrics.
Material Changes
There are no material changes to financial condition or operations reported in this filing. The document solely announces a corporate event.
Outlook, Commentary, and Events
Under Item 8.01 (Other Events), the Company announced it will present at the Cleveland Clinic's "Advances in Early Lung Cancer Detection" annual symposium. The presentation is scheduled for April 27, 2023, in Cleveland, Ohio. A press release regarding this event is attached as Exhibit 99.1.
Key Facts for Investor Verification
- Verify the date and location of the upcoming presentation at the Cleveland Clinic symposium (April 27, 2023).
- Review the attached press release (Exhibit 99.1) for specific details on the presentation content.
- Note that this filing contains no financial data; refer to the most recent 10-K or 10-Q for financial performance.